Remission of aHUS neurological damage with eculizumab

11Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Atypical haemolytic uraemic syndrome (aHUS) is a rare disease characterized by haemolytic microangiopathic anaemia, thrombocytopaenia and acute onset of renal failure, in the absence of Escherichia coli infection. Renal damage usually progresses to end-stage renal disease (ESRD), sometimes being accompanied by signs of extrarenal thrombotic microangiopathy (TMA). We report a case of full neurological and haematological recovery after eculizumab treatment in a patient with ESRD secondary to chronic aHUS refractory to plasmatherapy while she was under dialysis. It highlights the use of eculizumab for controlling extrarenal manifestations of aHUS in this population.

Cite

CITATION STYLE

APA

Ávila, A., Vizcaíno, B., Molina, P., Gavela, E., Perez-Ebri, M., & Pallardó, L. (2015). Remission of aHUS neurological damage with eculizumab. Clinical Kidney Journal, 8(2), 232–236. https://doi.org/10.1093/ckj/sfu144

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free